Cambrex to double size of Edinburgh solid form screening facility

30 Jul 2019

The expanded laboratory space will allow the installation of additional instruments and reactors for larger scale crystallization studies and solid form screening capabilities.

Cambrex is expanding its solid form screening and crystallization process development facility in Edinburgh, Scotland, doubling the current footprint to 15,000 sq. ft.

Cambrex to double size of Edinburgh solid form screening facility

The site currently has 50 employees and the expansion will add additional laboratory space to enable the recruitment of up to 40 more scientists, with the potential for further growth in the future.

Fit out is expected to begin in late August 2019 with a target completion date of the end of the year.

Cambrex’s Edinburgh site is a world-leader in providing solid form development services for drug substance and drug product. These include solid state investigations such as salt, co-crystal and polymorph screening, in addition to crystallization process development and GMP analytical services.

The expanded laboratory space will allow the installation of additional instruments and reactors for larger scale crystallization studies and solid form screening capabilities. Plans are in place for the installation of new ultra-performance liquid chromatography (UPLC) and gas chromatography instruments, as well as additional process analytical technology (PAT) tools.

“This strategic expansion, the increase in headcount and the investment in new equipment will enable us to serve more customers in the solid state screening market,” commented Mark Benger, Edinburgh Site Director, Cambrex. He added, “We have increasingly been asked by clients for additional services such as larger scale crystallization and we will now be able to provide these as well as adding greater efficiency and capacity at the Edinburgh site.”

Edinburgh became part of Cambrex’s global network of development and manufacturing facilities after the acquisition of Avista Pharma Solutions earlier this year. The facility was formerly known as Solid Form Solutions, an industry leader in solid state services, prior to the acquisition.

Read More

Related news

CPhI and AAPS partner to expand expert scientific content at CPhI North America

CPhI and AAPS partner to expand expert scientific content at CPhI North America

10 Jan 2020

CPhI and the American Association of Pharmaceutical Scientists (AAPS) today announced a partnership to expand the scientific content of activities sponsored by CPhI, including CPhI North America—the only event to bring the entire North American pharmac...

Read more 
Mylan recalls batches of Nizatidine capsules after nitrosamine detected in API

Mylan recalls batches of Nizatidine capsules after nitrosamine detected in API

9 Jan 2020

The US arm of generic and specialty pharma company Mylan Pharmaceuticals has recalled three lots of its heartburn drug Nizatidine in capsule form amid fears of possible nitrosamine contamination.

Read more 
New HQ for developer of world's first fully automated drug discovery platform

New HQ for developer of world's first fully automated drug discovery platform

8 Jan 2020

End-to-end robotic platform provides biotechnology companies, pharmaceutical corporations and academic centres with cost-effective and reproducible drug discovery data.

Read more 
Catalent completes purchase of biologics fill-finish and oral solid dose facility

Catalent completes purchase of biologics fill-finish and oral solid dose facility

7 Jan 2020

Facility provides European customers with great biologics and oral dose capabilities that can help reduce time-to-market.

Read more 
Boxing clever: Smart packs improving communication with patients

Boxing clever: Smart packs improving communication with patients

6 Jan 2020

Drug industry expectations of packaging are evolving with developers now seeking techs that help patients get more from their medicines.

Read more 
WuXi STA opens large-scale oligonucleotide manufacturing facility

WuXi STA opens large-scale oligonucleotide manufacturing facility

6 Jan 2020

Expands company's capacity and capability for this novel modality, providing a one-stop shop from preclinical to commercial.

Read more 
NIH researchers discover new autoinflammatory disease

NIH researchers discover new autoinflammatory disease

3 Jan 2020

Mutations in the RIPK1 gene responsible for CRIA syndrome.

Read more 
UCB to build new biotech manufacturing plant in Belgium

UCB to build new biotech manufacturing plant in Belgium

31 Dec 2019

Capacity to serve global late-stage development and commercial manufacturing of monoclonal antibody drug substance to support new product launches.

Read more 
BioAscent scientists help identify potential new treatments for cancer

BioAscent scientists help identify potential new treatments for cancer

30 Dec 2019

Collaboration discovers potent and selective inhibitors of enzymes associated with the development of some cancers and neurodegenerative diseases.

Read more 
Astellas strengthens immuno-oncology pipeline with acquisition of Xyphos Biosciences

Astellas strengthens immuno-oncology pipeline with acquisition of Xyphos Biosciences

27 Dec 2019

Acquisition adds talent and proprietary therapeutic platform to accelerate next-generation cancer immunotherapy.

Read more